Expert Interview
A Second Look: Discussing the results from the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment.
Ticker(s): PTGXInstitution: McGill (Jewish General Hospital)
- Assistant Professor of Oncology at McGill.
- Manages ~30 MF patients/month.
- Established the first myeloproliferative neoplasms clinic in Canada; has authored several publications in the area of MPN clinical research and has been an investigator on several clinical trials assessing novel agents in the treatment of MPN.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
